Corporate Satellite Symposia Schedule
Schedule is subject to change. Times are listed in Central Time (CST).
Wednesday, May 10
A New Approach for Reducing the Risk of Ototoxicity Associated with Cisplatin in Pediatric Patients 1 Month of Age and older, with Localized Non-Metastic Solid Tumors
The goal of this program is to introduce the new FDA-approved medication PEDMARK, indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients 1 month of age and older with localized, non-metastic sold tumors. Content will include a discussion of related clinical trials, dosing and administration, and safety.
Noah Federman, MD
Los Angeles, CA
This education theater is supported by Fennec Pharmaceuticals.
Friday, May 12
A Discussion on a Treatment Option for Sickle Cell Disease
Please join us to learn about the underlying pathophysiology of sickle cell disease. We will discuss the pathology of red blood cell sickling and how this leads to subsequent hemolysis and anemia. This program will also review the clinical efficacy and safety of a prescription treatment option for sickle cell disease.
This education theater is supported by Pfizer Inc.